Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

873703

registered interest
date	28/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Female Genital Mutilation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on the decision to disband its specialist team focused on combating female genital mutilation.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	134817
answer	answer is ministerial correction date of answer 20/04/2018 answer text <p>The Female Genital Mutilation (FGM) Prevention Programme funded by the Department and partnered with NHS England concluded on 31 March 2018 – it was always the intention that the Programme would conclude at this point.</p><p> </p><p>Since its launch, the Programme has worked closely with regional safeguarding teams across England, and these teams will be carrying on the work across the National Health Service in England to tackle FGM. Discussions, coordination and multi-agency work between the NHS and various partner agencies including the police and PPCs will therefore continue as part of this.</p><p> </p><p>Governance and monitoring and planning was built into the FGM Prevention Programme framework since its launch in 2014, including plans to conclude the Programme and arrangements for the work to be taken forward after April 2018.</p><p> </p><p>To support staff in their FGM prevention work, the FGM Prevention Programme developed a package of health-specific FGM materials providing guidance on safeguarding, commissioning of services, and guidance around the mandatory reporting duty It also held national awareness raising roadshows for over 6,000 professionals and commissioned comprehensive FGM e-learning with Health Education England, free to all NHS staff which has been completed by over 11,000 people on the e-learning for health website between January 2016 and February 2018.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 134819 134820 question first answered 20/04/2018 11:16:28 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4657 label Biography information for Anneliese Dodds

873704

registered interest
date	28/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Female Genital Mutilation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on how strategic planning to combat female genital mutilation will take place after the decision was taken to disband the specialist team focused on that issue.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	134818
answer	answer is ministerial correction date of answer 20/04/2018 answer text <p>The Female Genital Mutilation (FGM) Prevention Programme funded by the Department and partnered with NHS England concluded on 31 March 2018 – it was always the intention that the Programme would conclude at this point.</p><p> </p><p>Governance, monitoring and planning was built into the FGM Prevention Programme framework since its launch in 2014, including plans to conclude the Programme and arrangements for the work to be taken forward after April 2018. Since its launch, the Programme has worked closely with regional safeguarding teams across England, and these teams will be carrying on the work to tackle FGM across the National Health Service in England. Discussions, coordination and multi-agency work between the NHS and various partner agencies will also continue, now that the Programme has ended.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 20/04/2018 10:54:11 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4657 label Biography information for Anneliese Dodds

834378

registered interest
date	31/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with medicines manufacturers on the cost and ongoing viability of the production of medicines which currently have shared medicine packs with multiple EU countries.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	125997
answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>We are in regular contact with the pharmaceutical industry through the Ministerial and industry co-chaired United Kingdom-European Union Life Sciences Steering Group. Outside of this group we have consistent contact with industry and research charities. These discussions have included issues associated with shared packs and the implementation period for required regulatory and business operations changes post-Brexit. We will continue to discuss how disruption arising from our leaving the EU can be minimised for industry and supply to patients in the UK and European Member States.</p><p> </p><p>The UK is fully committed to continuing the close working relationship with our European partners, and as part of the negotiations the Government will discuss with the EU and Member States how best to continue cooperation in the field of medicines regulation (including with the European Medicines Agency).</p><p> </p><p>Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines, and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126001 question first answered 08/02/2018 12:18:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4657 label Biography information for Anneliese Dodds

834382

registered interest
date	31/01/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with medicines manufacturers on the minimum implementation period required to implement regulatory and business operations changes after the UK leaves the EU.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	126001
answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>We are in regular contact with the pharmaceutical industry through the Ministerial and industry co-chaired United Kingdom-European Union Life Sciences Steering Group. Outside of this group we have consistent contact with industry and research charities. These discussions have included issues associated with shared packs and the implementation period for required regulatory and business operations changes post-Brexit. We will continue to discuss how disruption arising from our leaving the EU can be minimised for industry and supply to patients in the UK and European Member States.</p><p> </p><p>The UK is fully committed to continuing the close working relationship with our European partners, and as part of the negotiations the Government will discuss with the EU and Member States how best to continue cooperation in the field of medicines regulation (including with the European Medicines Agency).</p><p> </p><p>Our aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines, and be assured that their safety is protected through the strongest regulatory framework and sharing of data.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 125997 question first answered 08/02/2018 12:18:08 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4657 label Biography information for Anneliese Dodds

789077

registered interest
date	14/11/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners: Voluntary Work
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance has been given to NHS general practices on the circumstances under which volunteers are permitted to carry out non-confidential medical work; and whether this guidance is the same as that for permitted activities of volunteers in other parts of the NHS.
tabling member constituency	Oxford East
tabling member printed	Anneliese Dodds
uin	113025
answer	answer is ministerial correction date of answer 22/11/2017 answer text <p>NHS England is responsible for ensuring those general practices who provide NHS services are issued with appropriate guidance on the management of volunteers. In September 2017, NHS England published guidance for all National Health Service providers to help them grow and develop volunteering. This equally applies to general practice as to other parts of the NHS. The guidance sets out that providers should include confidentiality and data protection information in a volunteering policy. The volunteer role description set out in the guidance states that all volunteers should ensure that patient confidentiality is maintained at all times.</p><p> </p><p>The guidance is available on the NHS England website:</p><p><a href="https://www.england.nhs.uk/publication/recruiting-and-managing-volunteers-in-nhs-providers-a-practical-guide/" target="_blank">https://www.england.nhs.uk/publication/recruiting-and-managing-volunteers-in-nhs-providers-a-practical-guide/</a></p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/11/2017 17:07:07 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4657 label Biography information for Anneliese Dodds